Dyne Therapeutics, a preclinical biotech developing therapies for muscular diseases, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering.
The company is using its proprietary FORCE platform to develop a pipeline of programs to address genetically-driven muscle diseases with high unmet need. This includes candidates for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral dystrophy (FSHD). Dyne expects to submit investigational new drug applications to the FDA for candidates in its DM1, DMD and FSHD programs between the 4Q 2021 and 4Q 2022.
The Waltham, MA-based company was founded in 2017 and plans to list on the Nasdaq under the symbol DYN. Dyne Therapeutics filed confidentially on July 23, 2020. J.P. Morgan, Jefferies, Piper Sandler and Stifel are the joint bookrunners on the deal. No pricing terms were disclosed.
The article Preclinical muscular disease biotech Dyne Therapeutics files for a $100 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.